Treatment barriers in PANS/PANDAS: Observations from eleven health care provider families.
- 1 September 2021
- journal article
- research article
- Published by American Psychological Association (APA) in Families, Systems, & Health
- Vol. 39 (3), 477-487
- https://doi.org/10.1037/fsh0000602
Abstract
Introduction: Pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS) are severe but highly treatable postinfectious inflammatory brain conditions. Despite published diagnostic and treatment guidelines for this condition, there are long delays in obtaining appropriate care. The reasons for these delays are poorly understood. We sought to identify health care system barriers to timely treatment by examining cases of PANDAS/PANS occurring in children of health care professionals. Method: We recruited families via e-mail request through the PANDAS Physicians Network. Participating parents completed a structured questionnaire and provided a written case description. Results: Eleven families completed data collection, representing a broad spectrum of disease (child disease onset age 4-15, 7 males/4 females, mild to severe). Parents included 11 physicians, 2 mental health professionals, 2 nurses, and a PharmD. Nine cases (82%) had "very delayed" diagnosis and treatment (>4 weeks after onset). The most commonly encountered causes for treatment delay were clinician lack of awareness (82%), clinician skepticism (82%), overdependence on diagnostic testing (91%), and out-of-pocket expenses >$100 US (82%). Other common challenges included difficulties finding a provider to spearhead care (64%), psychological misdiagnosis (55%), and children's suppression of behaviors during assessments (55%). Conclusions: We found numerous barriers to treatment of PANDAS/PANS among children of health care providers. Our findings suggest that even among the medically sophisticated, PANDAS/PANS diagnosis and treatment remains challenging. Improvement in PANDAS/PANS education of clinicians who may encounter children with this disorder is 1 key step toward addressing our identified barriers. Public Significance Statement Treatment barriers to families of children with PANS/PANDAS are very common and can delay access to effective treatment.Keywords
This publication has 16 references indexed in Scilit:
- Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part III—Treatment and Prevention of InfectionsJournal of Child and Adolescent Psychopharmacology, 2017
- Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part II—Use of Immunomodulatory TherapiesJournal of Child and Adolescent Psychopharmacology, 2017
- Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part I—Psychiatric and Behavioral InterventionsJournal of Child and Adolescent Psychopharmacology, 2017
- A Survey of Pediatric Acute-Onset Neuropsychiatric Syndrome Characteristics and CourseJournal of Child and Adolescent Psychopharmacology, 2017
- Impact of PANS and PANDAS Exacerbations on Occupational Performance: A Mixed-Methods StudyAmerican Journal of Occupational Therapy, 2017
- CNS autoimmune disease after Streptococcus pyogenes infections: animal models, cellular mechanisms and genetic factorsFuture Neurology, 2016
- Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cellsJCI Insight, 2015
- Clinical Evaluation of Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): Recommendations from the 2013 PANS Consensus ConferenceJournal of Child and Adolescent Psychopharmacology, 2015
- Passive transfer of streptococcus-induced antibodies reproduces behavioral disturbances in a mouse model of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infectionMolecular Psychiatry, 2009
- A Murine Model for Neuropsychiatric Disorders Associated with Group A β-Hemolytic Streptococcal InfectionJournal of Neuroscience, 2004